Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 18
Venture Financing 19
Ambrx Raises USD45 Million in Venture Financing 19
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 21
Private Equity 23
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 23
Partnerships 24
CMIC Enters and Fosun Pharma Enter into Joint Venture Agreement 24
Kite Pharma Forms Joint Venture with Fosun Pharma 25
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 26
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 27
Nature’s Sunshine Products Forms Joint Venture with Fosun Pharma 28
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 29
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 30
Atrium Innovations Forms Joint Venture With Fosun Industrial 31
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 32
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 33
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 34
Litha Pharma Partners with Gland Pharma 35
Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 36
Licensing Agreements 37
Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 37
Athenex to Enter into Licensing Agreement with Gland Pharma 38
Athenex to Enter into Licensing Agreement with Gland Pharma 39
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 40
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 41
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 42
Equity Offering 43
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 43
Chindex to Raise USD38.2 Million in Private Placement of Shares 45
Phagelux Raises Funds through Private Placement 46
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 47
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 48
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 49
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 50
Nature’s Sunshine Raises USD46 Million in Private Placement of Shares 51
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 53
Debt Offering 54
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 54
Shanghai Fosun Pharma Plans to Raise USD928 Million in Private Placement of Bonds 55
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 56
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 57
Shanghai Fosun Pharma Announces Public Offering Of Corporate Bonds To Raise Up To US$469.8 Million 58
Asset Transactions 59
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 59
Acquisition 60
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 60
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 61
Wuhan Mayinglong Pharma Sells 51% Stakes in Hubei Tianxiaming Pharma for USD2.9 Million 63
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 64
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 65
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 67
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 68
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 69
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 70
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 72
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 73
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 74
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 75
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 76
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 77
Fosun Pharma Acquires Additional Stake In Beijing Golden Elephant Pharmacy 78
Shanghai Fosun Pharma To Acquire 70% Stake In Jinzhou Ahon For US$213 Million 79
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 80
Shanghai Fosun Pharma Acquires 75% Stake In Dalian Aleph Bio-medical 81
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Competitors 82
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Employees 83
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Locations And Subsidiaries 85
Head Office 85
Other Locations & Subsidiaries 85
Joint Venture 85
Recent Developments 87
Corporate Communications 87
Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World’s Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 87
Jun 29, 2016: Shanghai Fosun Pharmaceutical (Group) Announces Resignation Of Non-Executive Director 90
Jun 07, 2016: Shanghai Fosun Pharmaceutical Announces Management Changes, Names New President and CEO 91
Mar 02, 2016: Resignation Of Non-Executive Director: Shanghai Fosun Pharmaceutical 93
Appendix 94
Methodology 94
About GlobalData 94
Contact Us 94
Disclaimer 94
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 18
Ambrx Raises USD45 Million in Venture Financing 19
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 21
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 23
CMIC Enters and Fosun Pharma Enter into Joint Venture Agreement 24
Kite Pharma Forms Joint Venture with Fosun Pharma 25
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 26
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 27
Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 28
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 29
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 30
Atrium Innovations Forms Joint Venture With Fosun Industrial 31
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 32
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 33
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 34
Litha Pharma Partners with Gland Pharma 35
Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 36
Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 37
Athenex to Enter into Licensing Agreement with Gland Pharma 38
Athenex to Enter into Licensing Agreement with Gland Pharma 39
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 40
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 41
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 42
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 43
Chindex to Raise USD38.2 Million in Private Placement of Shares 45
Phagelux Raises Funds through Private Placement 46
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 47
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 48
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 49
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 50
Nature's Sunshine Raises USD46 Million in Private Placement of Shares 51
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 53
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 54
Shanghai Fosun Pharma Plans to Raise USD928 Million in Private Placement of Bonds 55
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 56
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 57
Shanghai Fosun Pharma Announces Public Offering Of Corporate Bonds To Raise Up To US$469.8 Million 58
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 59
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 60
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 61
Wuhan Mayinglong Pharma Sells 51% Stakes in Hubei Tianxiaming Pharma for USD2.9 Million 63
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 64
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 65
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 67
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 68
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 69
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 70
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 72
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 73
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 74
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 75
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 76
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 77
Fosun Pharma Acquires Additional Stake In Beijing Golden Elephant Pharmacy 78
Shanghai Fosun Pharma To Acquire 70% Stake In Jinzhou Ahon For US$213 Million 79
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 80
Shanghai Fosun Pharma Acquires 75% Stake In Dalian Aleph Bio-medical 81
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Competitors 82
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Employees 83
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Subsidiaries 85
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Joint Venture 85